Shots:

• The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients who are alive and free of mechanical ventilation at day 29 of treatment while other EPs include clinical improvement- oxygen saturation & ICU admission
• The therapy has shown a reduction in cellular damage and lung edema in preclinical studies and may provide similar benefits in patients with severe SARS-CoV-2 infection. BI 764198 was well tolerated in P-I study in healthy adults
• BI 764198 is potent & selective inhibitor of TRPC6- focusing to reduce the need for ventilator support and to improve patient recovery rate

 ­ Ref: Boehringer Ingelheim | Image: Yicai Global